Article first published online: 8 JAN 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 17, Issue 3, pages 270–277, March 2008
How to Cite
Yang, T., Walker, M. C., Krewski, D., Yang, Q., Nimrod, C., Garner, P., Fraser, W., Olatunbosun, O. and Wen, S. W. (2008), Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidem. Drug Safe., 17: 270–277. doi: 10.1002/pds.1538
The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health.
No conflict of interest was declared.
- Issue published online: 25 FEB 2008
- Article first published online: 8 JAN 2008
- Manuscript Accepted: 19 NOV 2007
- Manuscript Received: 14 MAY 2007
- FDA pregnancy risk classification;
- chronic diseases;
- teenage pregnancy;
- social assistance;
To estimate the frequency of exposure to prescription Food and Drug Administration (FDA) category C, D, and X drugs in pregnant women, and to analyze the maternal characteristics associated with such an exposure.
A 50% random sample of women who gave a birth in Saskatchewan between January 1, 1997 and December 31, 2000 was chosen for the study. The rate of exposure to FDA category C, D, or X drugs recorded in the pharmacist database was estimated. Associations of exposure to FDA category C, D, and X drugs with maternal characteristics were evaluated using multiple logistical regression, with adjusted odds ratios (ORs) and its 95% confidence intervals (CIs) as the association measures.
A total of 18 575 women were included in this study. Among them, 3604 (19.4%) had exposure to one or more FDA category C, D, and X drugs during pregnancy. Category C drugs were the most frequently used drugs (15.8%), followed by D drugs (5.2%), and X drugs (3.9%). Women with chronic health conditions had fourfold at increased risk of exposure than women without. Regardless of health status, women who were <20 years of age, who had a parity ≥3, and who were on social assistance plan were at increased risk of pregnancy exposure to these drugs.
About 19.4% pregnant women are exposed to FDA C, D or X drugs during pregnancy. Women with chronic diseases, younger age, increased parity, and under social assistance are at increased risk of exposure to FDA C, D, or X drugs. Copyright © 2008 John Wiley & Sons, Ltd.